Trial Profile
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Belantamab mafodotin (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms DREAMM 2
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 16 Dec 2023 Planned End Date changed from 31 Aug 2023 to 1 Jul 2024.
- 22 Sep 2023 This trial has been completed in Spain (Date of the global end of the trial: 31-Mar-2022), according to the European Clinical Trials Database record.
- 25 Aug 2023 Final analysis of this study published in the Cancer.